Novel compound and use thereof
By developing a new compound with chemical formula 1, the skin irritation and aging caused by environmental pollution and stress are solved, and efficient defense and skin protection against reactive oxygen species are achieved, providing excellent antioxidant and anti-inflammatory effects.
Patent Information
- Application Number
- CN202380033000.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-06-08
- Filing Date
- 2023-06-08
- Publication Date
- 2024-11-26
Smart Images

Figure CN119032076A_ABST
Abstract
Description
Technical Field
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to Korean Invention Patent Application No. 2022-0069329 filed on June 8, 2022, the entire contents of which are hereby incorporated by reference into this specification.
[0003] The present invention relates to a novel compound having antioxidant effect and its use. Background Art
[0004] As the largest organ of the human body, the skin is in constant direct contact with the external environment while acting as a protective membrane, protecting the organism from various stimuli and dry environments. Compared with other organs, the skin is an organ where the generation and death of new cells are very active. In addition, the skin plays an important role in protecting the body from physical abrasions, preventing the loss of water in the body, protecting the body from the effects of ultraviolet rays in sunlight, and regulating body temperature.
[0005] However, in recent years, factors threatening skin health have increased, for example, due to environmental pollution, the ultraviolet rays reaching the earth's surface have increased, exposure to environmental pollutants such as particulate matter, westernized lifestyles, pressure, etc. These factors not only cause skin pollution, dryness, and allergies, but also lead to abnormalities in the skin immune system, ultimately causing dermatitis, skin keratinization (roughness), accelerated aging, and other problems. In particular, environmental pollution and various pressures increase the concentration of active oxygen in the body, and these active oxygens attack the components of cells such as lipids, proteins, sugars, and DNA to cause peroxidation, thereby accelerating skin aging. Therefore, there is still a need for a composition that can provide effective defense capabilities and excellent antioxidant capacity to the skin irritation sources caused by environmental pollution and various pressures.
[0006] The present inventors have devoted themselves to developing novel compounds that are safe, have improved antioxidant capacity, and exhibit anti-aging effects, and ultimately confirmed that the compound represented by Chemical Formula 1 not only has excellent antioxidant activity but also exhibits dosage form stability, thereby completing the present invention. Summary of the invention
[0007] Technical issues
[0008] An object of the present disclosure is to provide a novel compound or a pharmaceutically acceptable salt thereof that exhibits excellent antioxidant activity.
[0009] Another object of the present disclosure is to provide a method for preparing the above-mentioned novel compound.
[0010] Another object of the present disclosure is to provide a pharmaceutical composition comprising the compound according to the present disclosure or a pharmaceutically acceptable salt thereof as an active ingredient.
[0011] Another object of the present disclosure is to provide a cosmetic composition comprising the compound according to the present disclosure or a cosmetically acceptable salt thereof as an active ingredient.
[0012] Technical Solution
[0013] As one embodiment for achieving the above object, a compound represented by the following Chemical Formula 1, an isomer thereof, or a pharmaceutically acceptable salt thereof is provided.
[0014] Chemical formula 1
[0015]
[0016] In the above formula,
[0017] R 1 To R 4 are independently hydrogen, C1-C 12 Alkyl, preferably C1-C6 alkyl, more preferably C1-C3 alkyl, C1-C 12 Acyl, preferably C1-C6 acyl, more preferably C1-C3 acyl or C3-C 12 Cycloalkyl, preferably C3-C6 cycloalkyl, more preferably C3-C6 cycloalkyl,
[0018] X is hydrogen, fluorine, chlorine, methyl or methoxy.
[0019] More specifically, the compound represented by Chemical Formula 1 according to the present disclosure may be selected from the group consisting of compounds having the following structures:
[0020]
[0021]
[0022]
[0023]
[0024] More specifically, the compound represented by Chemical Formula 1 according to the present disclosure may be selected from the group consisting of the following compounds:
[0025] 4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)benzyl-(E)-3-(3,4-dihydroxyphenyl)acrylate;
[0026] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)benzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate;
[0027] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-benzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate;
[0028] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-2-methylbenzy l-3-(4-acetoxy-3-hydroxyphenyl)acrylate;
[0029] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-3-methylbenz yl-3-(4-acetoxy-3-methoxyphenyl)acrylate;
[0030] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-3-methylbenzy l-3-(4-acetoxy-3-hydroxyphenyl)acrylate;
[0031] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)benzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate;
[0032] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acrloyl)oxy)-3-methylbenzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate;
[0033] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy-2-methylbenzyl-3-(4-acetoxy-3-hydroxyphenyl)acryalate;
[0034] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-2-methoxybenzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate;
[0035] (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)-2-methylbenz yl-3-(4-hydroxy-3-methoxyphenyl)acrylate;
[0036] (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)-3-methylbenz yl-3-(4-hydroxy-3-methoxyphenyl)acrylate;
[0037] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-methoxybenzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate;
[0038] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-methylbenzl y-3-(4-acetoxy-3-methoxyphenyl)acrylate;
[0039] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)benzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate;
[0040] (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)-3-methylbenzl y-3-(4-hydroxy-3-methoxyphenyl)acrylate;
[0041] (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)-2-methylbenzl y-3-(4-hydroxy-3-methoxyphenyl)acrylate;
[0042] (E)-4-(((E)-3-(3,4-dimethoxyphenyl)acryloyl)oxy)-2-methoxybenzyl-3-(3,4-dimethoxyphenyl)acrylate;
[0043] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-methylbenz yl-3-(4-acetoxy-3-methoxyphenyl)acrylate;
[0044] (E) 4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-3-fluorobenzyl-3-(3,4-dihydroxyphenyl)acrylate;
[0045] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-3-fluorobenzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate;
[0046] ((E)-2-fluoro-4-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)methyl)phenyl-3-(4-hydroxy-3-methoxyphenyl)acrylate;
[0047] (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-3-chlorobenzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate;
[0048] (E)-2-fluoro-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)methyl)phenyl-3-(4-hydroxy-3-methoxyphenyl)acrylate;
[0049] (E)-3-fluoro-4-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)meth yl)phenyl-3-(4-hydroxy-3-methoxyphenyl)acrylate;
[0050] (E)-2-fluoro-4-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)meth yl)phenyl-3-(4-hydroxy-3-methoxyphenyl)acrylate and
[0051] (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-fluorobenzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate
[0052] In addition, the present disclosure provides a method for preparing the compound represented by the Chemical Formula 1, which includes the step of reacting (E)-3-(3,4-dihydroxyphenyl)acrylic acid as a starting material.
[0053] In another aspect, the present disclosure provides a pharmaceutical composition comprising, as an effective ingredient, a compound represented by Chemical Formula 1, an isomer thereof, or one or more pharmaceutically acceptable salts thereof. The pharmaceutical composition according to the present disclosure is suitable for providing an antioxidant effect to a subject.
[0054] In addition, the compounds according to the present disclosure can be used to prevent or treat diseases caused or mediated by oxidative stress in the body, particularly reactive oxygen species (ROS). These diseases are not limited thereto, and may include degenerative neurological diseases including arteriosclerosis, Lou Gehrig's disease, Parkinson's disease, Alzheimer's disease, amyotrophic lateral sclerosis and Huntington's disease, cardiovascular diseases including myocardial infarction, angina pectoris, coronary artery disease, ischemic heart disease, ischemic brain diseases including stroke, diabetes, digestive system diseases including gastritis and gastric cancer, cancer, leukemia, aging, rheumatoid arthritis, hepatitis, atopic dermatitis and other diseases, specifically aging caused by reactive oxygen species.
[0055] In the present specification, the term "prevention" refers to all actions to inhibit or delay the occurrence, spread and recurrence of diseases induced or mediated by oxidative stress (especially reactive oxygen species) in the body by administering the compounds of the present disclosure or compositions comprising the same, and "treatment" refers to all actions to improve or make the above-mentioned disease symptoms favorable by administering the compositions of the present disclosure.
[0056] The composition of the present invention can be prepared into oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc. according to various purposes of use in a conventional manner, and various forms such as injections of sterile injection solutions are prepared and used, and can be orally administered or administered by various routes including intravenous, intraperitoneal, subcutaneous, rectal, and topical administration. Suitable carriers, excipients, or diluents that may be included in such compositions may include lactose, glucose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methylcellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, etc. In addition, the composition of the present invention may further include fillers, anticoagulants, lubricants, wetting agents, spices, emulsifiers, preservatives, etc.
[0057] Solid preparations for oral administration include tablets, pills, powders, granules, capsules, etc., which are prepared by mixing at least one excipient (e.g., starch, calcium carbonate, sucrose, lactose, gelatin, etc.) in the composition. In addition, lubricants such as magnesium stearate, talc, etc. can be used in addition to simple excipients.
[0058] Oral liquid preparations include suspensions, oral solutions, emulsions, syrups, etc., and may include various excipients (for example, wetting agents, sweeteners, aromatics, preservatives, etc.) in addition to commonly used simple diluents such as water and liquid paraffin.
[0059] Preparations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations and suppositories.
[0060] Non-aqueous solvents and suspending agents may include propylene glycol, polyethylene glycol, vegetable oils (e.g., olive oil), injectable esters (e.g., ethyl oleate), etc. The base of the suppository may use witepsol, polyethylene glycol, Tween 61, cocoa butter, lauric acid glyceride fat, glycerin gelatin, etc. On the other hand, the injection may include existing additives such as solubilizers, isotonic agents, selection aids, emulsifiers, stabilizers, preservatives, etc.
[0061] The preparation can be prepared by conventional mixing, granulation or coating methods, and can contain about 0.1 weight percent to 75 weight percent of the compound according to the present disclosure, preferably about 1 weight percent to 50 weight percent. The unit dosage form for a mammal weighing about 50kg to 70kg can contain about 10mg to 200mg of the compound according to the present disclosure.
[0062] The composition of the present invention is applied in a pharmaceutically effective amount. In this specification, the term "pharmaceutically effective amount" refers to an amount that is sufficient to treat with a reasonable benefit / risk ratio applicable to medical treatment and does not cause side effects, and the effective dose level can be determined according to the patient's health, disease type, severity, drug activity, sensitivity to drugs, application method, route of administration and excretion rate, treatment time, factors including mixed or simultaneously used drugs, and other factors known in the medical field. The composition of the present disclosure can be applied with a single therapeutic agent or co-administered with other therapeutic agents, can be applied sequentially or simultaneously with existing therapeutic agents, and single or multiple administrations. It is important to apply the amount that can obtain the maximum effect with a minimum amount in consideration of all the above factors and without side effects, which can be easily determined by a technician in the field.
[0063] The preferred dosage of the compound of the present disclosure varies according to the patient's condition and body weight, degree of illness, form of the drug, route of administration and time of administration, but it can be appropriately selected by a person skilled in the art. However, in order to achieve the desired effect, when applied to a human subject, it is appropriate to administer 0.0001 mg / kg to 100 mg / kg (body weight) of the compound of the present disclosure every day, preferably 0.001 mg / kg to 100 mg / kg (body weight). It can be administered once a day or administered multiple times by oral or parenteral routes.
[0064] In addition, the present disclosure provides a method for preventing or treating a disease induced or mediated by reactive oxygen species, comprising the step of administering the pharmaceutical composition to a subject in need thereof.
[0065] In the present disclosure, the term "subject" refers to all animals including monkeys, cattle, horses, sheep, pigs, chickens, turkeys, quails, cats, dogs, mice, rats, rabbits or guinea pigs, including humans who have or may have the disease induced or mediated by oxidative stress (especially reactive oxygen species) in the body, and the disease can be effectively prevented or treated by administering the pharmaceutical composition of the present disclosure to the subject. The pharmaceutical composition of the present disclosure can be administered in combination with existing therapeutic agents.
[0066] In the present disclosure, the term "administer" refers to providing a predetermined substance to a patient by any appropriate method, and the composition of the present disclosure can be administered by any conventional route, as long as it can reach the intended tissue. It can be administered intraperitoneally, intravenously, intramuscularly, subcutaneously, intradermally, orally, topically, intranasally, intrapulmonaryly, and intrarectally, but is not limited thereto. In addition, the pharmaceutical composition of the present disclosure can be administered by any device capable of delivering the active substance to the target cell. Preferred administration methods and formulations are intravenous injections, subcutaneous injections, intradermal injections, intramuscular injections, and drops. Injections can be prepared using aqueous solvents such as physiological saline and Ringer's solution, non-aqueous solvents such as vegetable oils, higher fatty acid esters (e.g., ethyl oleate, etc.), alcohols (e.g., ethanol, benzyl alcohol, propylene glycol, glycerol, etc.), and the like, and may include stabilizers for preventing deterioration (e.g., ascorbic acid, sodium bisulfite, sodium metabisulfite, BHA, tocopherol, EDTA, etc.), emulsifiers, buffers for adjusting the pH value, preservatives for inhibiting the growth of microorganisms (e.g., phenylmercuric nitrate, thimerosal, benzalkonium chloride, phenol, cresol, benzyl alcohol, etc.), and the like drug carriers.
[0067] In another embodiment, the present disclosure provides a cosmetic composition comprising, as an effective ingredient, a compound represented by Chemical Formula 1, an isomer thereof, or one or more cosmetically acceptable salts thereof. The cosmetic composition according to the present disclosure can provide an antioxidant effect or an anti-inflammatory effect by topical application.
[0068] The content of the active ingredient in the cosmetic composition according to the present disclosure may be 0.00001 weight percent to 99.99 weight percent, specifically, 0.0001 weight percent to 50 weight percent, more specifically, 0.002 weight percent to 30 weight percent, based on the weight of the composition, but is not limited thereto.
[0069] In this specification, the term "antioxidant" refers to the effect of inhibiting oxidation. The human body maintains a balance between pro-oxidants and antioxidants, but various factors destroy this equilibrium state, and if it tends to be pro-oxidants, it will induce oxidative stress, thereby leading to potential cell damage and pathological diseases. As the direct cause of this oxidative stress, reactive oxygen is unstable and highly reactive, and it is easy to react with various substances in the body and attack macromolecules in the body, thereby causing irreversible damage to cells and tissues or causing mutations, cytotoxicity and carcinogenesis. When an inflammatory reaction occurs, a large amount of reactive nitrogen (reactive nitrogen species, RNS) (for example, NO, HNO2, ONOO, etc.) is produced due to the immune response of macrophages, neutrophils and other immune cells, and reactive oxygen (ROS) is also produced at this time. The reactive oxygen as described above oxidizes and destroys cells in the body, thereby exposing the human body to various diseases. Therefore, including the compounds of the present disclosure in cosmetics can achieve an antioxidant effect, thereby helping to promote health.
[0070] In this specification, the term "cosmetic composition" can be made into the form of conventional emulsified formulations and solubilized formulations. Examples of the emulsified formulations include nutrient water, cream, essence, etc., and examples of the solubilized formulations include skin softening water, etc. Suitable formulations are not limited thereto, and may be, for example, solutions, gels, solid or pasty anhydrous products, emulsions obtained by dispersing an oil phase in an aqueous phase, suspensions, microemulsions, microcapsules, microparticles or ions (liposomes), non-ionic carrier dispersant forms, creams, skin lotions, emulsions, powders, ointments, sprays or concealer sticks. In addition, it may be in the form of a foam or an aerosol composition further containing a compressed propellant.
[0071] The cosmetic composition according to the present disclosure may further contain conventionally used auxiliary agents, such as fatty substances, organic solvents, solubilizers, thickeners and gelling agents, emollients, antioxidants, suspending agents, stabilizers, foaming agents, fragrances, surfactants, water, ionic or non-ionic emulsifiers, fillers, masking agents, chelating agents, preservatives, vitamins, retardants, moisturizers, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, lipid carriers or any other ingredients conventionally used in cosmetic compositions, etc.
[0072] On the other hand, the compounds of the present disclosure can exist in the form of salts, particularly in the form of pharmaceutically acceptable salts or cosmetically acceptable salts. Salts can be used without restriction in the conventionally used salts in the art, for example, acid addition salts formed by pharmaceutically acceptable free acids (free acid). In this specification, the term "pharmaceutically acceptable salt", "cosmetically acceptable salt" refers to any organic or inorganic addition salts of the above-mentioned compounds, and its concentration is relatively non-toxic and harmless to the subject and has an effective effect, and the side effects caused by the above-mentioned salts do not reduce the beneficial effects of the compound represented by Chemical Formula 1.
[0073] Acid addition salts can be prepared by conventional methods, for example, by dissolving the compound with an excess of aqueous acid solution and precipitating the salt with a water-soluble organic solvent (for example methanol, ethanol, acetone or acetonitrile). Can heat the compound in equimolar amounts and the acid or alcohol (for example, ethylene glycol monomethyl ether) in water, then evaporate the mixture to dry, or filter the precipitated salt with suction.
[0074] At this time, the free acid may be an organic acid or an inorganic acid. The inorganic acid may be hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, etc.; the organic acid may be methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, mandelic acid, propionic acid, citric acid, lactic acid, glycolic acid, glucuronic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid, aspartic acid, ascorbic acid, carbonic acid, vanillic acid, hydroiodic acid, etc., but is not limited thereto.
[0075] In addition, a base can be used to prepare a pharmaceutically or cosmetically acceptable metal salt. Alkali metal salts or alkaline earth metal salts can be obtained, for example, by dissolving the compound in an excess of an alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and then evaporating and drying the filtrate. At this time, in terms of pharmacy, cosmetics or food science, it is suitable to prepare sodium, potassium or calcium salts as metal salts, but is not limited thereto. In addition, the corresponding silver salt can be obtained by reacting an alkali metal or alkaline earth metal salt with an appropriate silver salt (e.g., silver nitrate).
[0076] Pharmaceutically acceptable salts of the compounds of the present disclosure include salts of acidic or basic groups that may be present in the above chemical formula 1, unless otherwise specified. For example, pharmaceutically or cosmetically acceptable salts may include sodium, calcium and potassium salts of hydroxyl groups, and other pharmaceutically acceptable salts of amino groups may include hydrobromide compounds, phosphates, hydrogen phosphates, phosphates, hydrogen phosphates, dihydrogen phosphates, acetates, succinates, citrates, tartrates, lactates, mandelates, methanesulfonates and p-toluenesulfonates (toluenesulfonates), etc., which can be prepared by salt preparation methods known in the art.
[0077] In addition, the compound represented by the above Chemical Formula 1 according to the present disclosure includes, without limitation, possible solvates such as hydrates that can be prepared therefrom and all possible stereoisomers, in addition to its pharmaceutically acceptable salts. The solvates and stereoisomers of the compound represented by the above Chemical Formula 1 can be prepared from the compound represented by Chemical Formula 1 by methods known in the art.
[0078] In addition, the compound represented by the chemical formula 1 according to the present disclosure is prepared in a crystalline form or an amorphous form, and when prepared in a crystalline form, it can be arbitrarily hydrated or solvated. The present disclosure includes not only stoichiometric hydrates of the compound represented by the chemical formula 1, but also compounds containing different amounts of water. The solvates of the compound represented by the chemical formula 1 according to the present disclosure include both stoichiometric solvates and non-stoichiometric solvates.
[0079] Effects of the Invention
[0080] The novel compound represented by Chemical Formula 1 according to the present disclosure may provide excellent anti-oxidation effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0081] Figure 1 is a diagram showing a reaction formula for preparing 4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)benzyl (E)-3-(3,4-dihydroxyphenyl)acrylate according to an embodiment of the present disclosure.
[0082] Figure 2 is a graph showing the results of a cytotoxicity experiment according to Experimental Example 1.
[0083] Figure 3 is a graph showing the results of an antioxidant experiment according to Experimental Example 2.
[0084] Figure 4 This is a graph showing the results of confirming the active oxygen suppressive ability according to Experimental Example 3.
[0085] Figure 5 These are the results of confirming the active oxygen suppressive ability according to Experimental Example 3 by DCF-DA. DETAILED DESCRIPTION
[0086] Hereinafter, the present disclosure is described in detail through specific embodiments to enable those skilled in the art to easily implement the present disclosure. However, the present disclosure can be implemented in various forms and is not limited to the embodiments described herein.
[0087] Preparation Example 1: Preparation of (E)-3-(3,4-diacetoxyphenyl)acrylic acid ((E)-3-(3,4- diacetoxyphenyl)acrylic acid)
[0088] (E)-3-(3,4-dihydroxyphenyl)acrylic acid (3.0 g, 1.0 eq.) and pyridine (1.97 ml, 1.5 eq.) were placed in a reactor and cooled to 0 to 5°C at room temperature. Acetic anhydride (8.5 g, 5.0 eq.) was slowly added at the same temperature for 10 to 20 minutes, and stirred at room temperature for more than 18 hours. Methylene chloride (10 ml) and n-heptane (30 ml) were placed in the reaction solution and stirred at room temperature for more than 1 hour. After filtering the solid compound, it was vacuum dried at 40°C for more than 12 hours to obtain a compound according to the following chemical formula 2 (3.5 g, yield 79.7%).
[0089] Chemical formula 2
[0090]
[0091] Preparation Example 2: Preparation of 4-((E)-3-((4-(((E)-3-(3,4-diacetoxyphenyl)acryloyl)oxy)benzyl (4-((E)-3-((4-(((E)-3-(3,4- diacetoxyphenyl)acryloyl)oxy)benzyl)oxy)-3-oxoprop-1-en-1-yl)-1,2- phenylenediacetate)
[0092] (E)-3-(3,4-diacetoxyphenyl)acrylic acid (1.7 g, 2.1 eq.) prepared in the above Preparation Example 1 was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. Thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)) was slowly added and stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). p-Hydroxybenzyl alcohol (gastrodigenin, Aldrich) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were placed in reactor B and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly added to reactor B over 10 to 20 minutes at room temperature and stirred under reflux for more than 2 hours. After the reaction was completed, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound represented by the following Chemical Formula 3 (1.1 g, yield 55.5%).
[0093] Chemical formula 3
[0094]
[0095] 1 H-NMR (400MHz, DMSO-d6) δ7.84-7.68 (m, 6H), 7.52-7.50 (d, 2H), 7.38-7.31 (m, 2H), 7.2 6-7.23 (d, 2H), 6.92-6.88 (d, 1H), 6.75-6.71 (d, 1H), 5.25 (s, 2H), 2.31-2.28 (m, 12H).
[0096] Example 1: Preparation of 4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)benzyl (E)-3-(3,4-dihydroxyphenyl)acryloyl 4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)benzyl(E)-3-(3,4- dihydroxyphenyl)acrylate
[0097] Figure 1 The figure shows the reaction formula for preparing 4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)benzyl (E)-3-(3,4-dihydroxyphenyl)acrylate.
[0098] The (4-((E)-3-((4-(((E)-3-(3,4-diacetoxyphenyl)acryloyl)oxy)benzyl)oxy)-3-oxoprop-1-en-1-yl)-1,2-benzenediacetate) and dioxane (5 ml) prepared in the above Preparation Example 2 were placed in a reactor, 2N sodium hydroxide (NaOH) (2.0 g, 5 eq.) was added, and the mixture was stirred at 50°C for more than 3 hours. After the reaction was terminated, the mixture was cooled to room temperature, 10% hydrochloric acid (HCl) (10 ml) and ethyl acetate (15 ml) were added, and the mixture was stirred for more than 30 minutes. The organic layer was extracted, dehydrated with magnesium sulfate (MgSO4), and concentrated under reduced pressure. The mixture was vacuum dried at 40°C for more than 10 hours to obtain a compound according to Chemical Formula 4 (0.18 g, yield 50.0%).
[0099] Chemical formula 4
[0100]
[0101] 1 H-NMR (400MHz, DMSO-d6) δ7.70-7.66(d, 1H), 7.55-7.51(d, 1H), 7.49-7.47(d, 2H), 7.21-7.19(d , 2H), 7.14-7.01(m, 4H), 6.80-6.75(m, 2H), 6.51-6.47(d, 1H), 6.35-6.31(d, 1H), MS(ESI+): m / z 449.12[M+H]+ .
[0102] Example 2: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)benzyl-3- (4-acetoxy-3-hydroxyphenyl) acrylate acryloyl)oxy)benzyl-3-(4-a cetoxy-3-hydroxyphenyl)acrylate)
[0103] (E)-3-(3-hydroxy4-acetoxyphenyl)acrylic acid acid) (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen environment. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), stir at room temperature for more than 1 hour. After concentrating thionyl chloride under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen environment (reactor A). p-Hydroxybenzyl alcohol (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were placed in reactor B and stirred at room temperature for more than 30 minutes. After slowly placing the material in reactor A into reactor B at room temperature for 10 to 20 minutes, stir and reflux for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 5.
[0104] Chemical formula 5
[0105]
[0106] 1 H-NMR (400MHz, DMSO-d6) δ9.46 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 6H), 6.80-6.75 (m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H), 2.18 (s, 6H)
[0107] MS (ESI+): m / z 533.12 [M+H] + .
[0108] Example 3: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)benzyl- 3-(4-Acetoxy-3-methoxyphenyl)acrylate ((E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)benzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate)
[0109] (E)-3-(3-Methoxy-4-acetoxyphenyl)acrylic acid acid) (purchased from Sigma-Aldrich) is placed in a reactor and cooled to 0°C to 5°C under a nitrogen environment. After slowly adding thionyl chloride (SOCl2) (3.4ml, exess (3~5eq.)), stir at room temperature for more than 1 hour. After concentrating thionyl chloride under reduced pressure, put anhydrous dichloromethane (10ml) under a nitrogen environment (reactor A). p-Hydroxybenzyl alcohol (0.4g, 1.0eq.), anhydrous dichloromethane (5ml) and triethylamine (0.7g, 2.2eq.) are placed in reactor B and stirred at room temperature for more than 30 minutes. After slowly placing the material in reactor A into reactor B at room temperature for 10 to 20 minutes, stir and reflux for more than 2 hours. After the reaction is terminated, the reaction solution is concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 6.
[0110] Chemical formula 6
[0111]
[0112] 1 H-NMR (400MHz, DMSO-d6) δ7.55-7.53 (d, 2H), 7.25-7.19 (m, 6H), 6.80-6.75 (m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H), 3.68 (s, 6H), 2.18 (s, 6H)
[0113] MS (ESI+): m / z 561.12 [M+H] + .
[0114] Example 4: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-2-methyl Benzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate hydroxyphenyl)acryloyl)oxy)-2-methylben zyl-3-(4-acetoxy-3-hydroxyphenyl) acrylate
[0115] (E)-3-(3-hydroxy-4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-methyl-4-hydroxybenzyl alcohol (2-methyl-4-hydroxybenzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 7.
[0116] Chemical formula 7
[0117]
[0118] 1 H-NMR (400MHz, DMSO-d6) δ9.46 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H) , 6.80-6.75(m, 4H), 6.35-6.31(d, 2H), 5.2(s, 2H), 2.31(s, 3H), 2.18(s, 6H)
[0119] MS (ESI+): m / z 547.15 [M+H] + .
[0120] Example 5: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-methoxyphenyl Benzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate ((E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-methylbe nzyl-3-(4-acetoxy-3-methoxyphenyl) acrylate
[0121] (E)-3-(3-methoxy, 4-acetoxyphenyl)acrylic acid (((E)-3-(3-methoxy4-acetoxyphenyl)acrylic acid) (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-methyl-4-hydroxybenzyl alcohol (2-methyl-4-hydroxy benzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 8.
[0122] Chemical formula 8
[0123]
[0124] 1 H-NMR (400MHz, DMSO-d6) δ7.55-7.53(d, 2H), 7.25-7.19(m, 5H), 6.80-6.75( m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H), 3.68 (s, 6H), 2.29 (s, 3H), 2.18 (s, 6H).
[0125] MS (ESI+): m / z 575.16 [M+H] + .
[0126] Example 6: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-3-methyl Benzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate ((E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-3-methylben zyl-3-(4-acetoxy-3-hydroxyphenyl) acrylate
[0127] (E)-3-(3-hydroxy-4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 3-methyl-4-hydroxybenzyl alcohol (3-methyl-4-hydroxybenzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.), and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed in reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure, and column chromatography was performed using ethyl acetate / n-heptane as a developing solvent to obtain a compound according to the following chemical formula 9.
[0128] Chemical formula 9
[0129]
[0130] 1 H-NMR (400MHz, DMSO-d6) δ9.46 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H) , 6.80-6.75(m, 4H), 6.35-6.31(d, 2H), 5.2(s, 2H), 2.18(s, 6H), 2.15(s, 3H).
[0131] MS (ESI+): m / z 547.15 [M+H] + .
[0132] Example 7: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-3-methoxyphenyl Benzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate ((E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-3-methylbe nzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate)
[0133] (E)-3-(3-methoxy-4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 3-methyl-4-hydroxybenzyl alcohol (3-methyl-4-hydroxybenzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 10.
[0134] Chemical formula 10
[0135]
[0136] 1 H-NMR (400MHz, DMSO-d6) δ7.55-7.53(d, 2H), 7.25-7.19(m, 5H), 6.80-6.75( m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H), 3.67 (s, 3H), 2.18 (s, 6H), 2.15 (s, 3H).
[0137] MS (ESI+): m / z 575.15 [M+H] + .
[0138] Example 8: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-2-methoxy Benzyl-3-(4-acetoxy-3-hydroxyphenyl)acrylate hydroxyphenyl)acryloyl)oxy)-2-methoxyb enzyl-3-(4-acetoxy-3-hydroxyphenyl) acrylate
[0139] (E)-3-(3-hydroxy-4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-methoxy-4-hydroxybenzyl alcohol (2-methoxy-4-hydroxybenzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 11.
[0140] Chemical formula 11
[0141]
[0142] 1 H-NMR (400MHz, DMSO-d6) δ9.46 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H) , 6.80-6.75(m, 4H), 6.35-6.31(d, 2H), 5.2(s, 2H), 3.73(s, 3H), 2.18(s, 6H)
[0143] MS (ESI+): m / z 563.15 [M+H] + .
[0144] Example 9: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-methoxyphenyl Oxybenzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate
[0145] ((E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-methoxyb enzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate)
[0146] (E)-3-(3-methoxy-4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-methoxy-4-hydroxybenzyl alcohol (2-methoxy-4-hydroxy benzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 12.
[0147] Chemical formula 12
[0148]
[0149] 1 H-NMR (400MHz, DMSO-d6) δ7.55-7.53(d, 2H), 7.25-7.19(m, 5H), 6.80-6.75( m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H), 3.73 (s, 3H), 3.68 (s, 6H), 2.18 (s, 6H)
[0150] MS (ESI+): m / z 591.15 [M+H] + .
[0151] Example 10: Preparation of (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)-2-methylbenzyl (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl) acrylate acryloyl)oxy)-2-methylbe nzyl-3-(4-hydroxy-3-methoxyphenyl)acrylate)
[0152] (E)-3-(3-methoxy-4-hydroxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-methyl-4-hydroxybenzyl alcohol (2-methyl-4-hydroxybenzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 13.
[0153] Chemical formula 13
[0154]
[0155] 1 H-NMR (400MHz, DMSO-d6) δ9.55 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H) , 6.80-6.75(m, 4H), 6.35-6.31(d, 2H), 5.2(s, 2H), 3.68(s, 6H), 2.29(s, 3H).
[0156] MS (ESI+): m / z 491.16 [M+H] + .
[0157] Example 11: Preparation of (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)-3-methylbenzyl (E)-4-(((E)-3-(4-hydroxy-3-methoxyphenyl) acrylate acryloyl)oxy)-3-methylbe nzyl-3-(4-hydroxy-3-methoxyphenyl)acrylate)
[0158] (E)-3-(3-methoxy-4-hydroxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 3-methyl-4-hydroxybenzyl alcohol (3-methyl-4-hydroxybenzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 14.
[0159] Chemical formula 14
[0160]
[0161] 1 H-NMR (400MHz, DMSO-d6) δ9.55 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H) , 6.80-6.75(m, 4H), 6.35-6.31(d, 2H), 5.2(s, 2H), 3.68(s, 6H), 2.15(s, 3H).
[0162] MS (ESI+): m / z 491.16 [M+H] + .
[0163] Example 12: Preparation of (E)-4-(((E)-3-(3,4-dimethoxyphenyl)acryloyl)oxy)-2-methoxybenzyl (E)-4-(((E)-3-(3,4-dimethoxyphenyl)acryloyl) oxy)-2-methoxybenzyl-3-(3,4-dimethoxyphenyl)acrylate)
[0164] (E)-3-(3,4-dimethoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-methyl-4-hydroxybenzyl alcohol (2-methyl-4-hydroxybenzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 15.
[0165] Chemical formula 15
[0166]
[0167] 1 H-NMR (400MHz, DMSO-d6) δ7.55-7.53(d, 2H), 7.25-7.19(m, 5H), 6.80-6.75(m, 4H), 6.35-6.31(d, 2H), 5.2(s, 2H), 3.73(s, 3H), 3.68(s, 12H).
[0168] MS (ESI+): m / z 535.15 [M+H] + .
[0169] Example 13: Preparation of (E)4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-3-fluorobenzyl-3-(3,4-dihydroxyphenyl)acryloyl (E)-4-(((E)-3-(3,4-dihydroxyphenyl)acryloyl)oxy)-3- fluorobenzyl-3-(3,4-dihydroxyphenyl)acrylate)
[0170] The (E)-3-(3,4-diacetoxyphenyl)acrylic acid prepared in the above Preparation Example 1 was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was added under a nitrogen atmosphere (reactor A). 3-Fluoro-4-hydroxy benzyl alcohol (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were placed in reactor B and stirred at room temperature for more than 30 minutes. After slowly adding the material in reactor A to reactor B over 10 to 20 minutes at room temperature, the mixture was stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following Chemical Formula 16.
[0171] Chemical formula 16
[0172]
[0173] 1 H-NMR (400MHz, DMSO-d6) δ9.55 (s, 4H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H), 6.80-6.75 (m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H).
[0174] MS (ESI+): m / z 467.11 [M+H] + .
[0175] Example 14: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-hydroxyphenyl)acryloyl)oxy)-3-chlorobenzyl 3-(4-acetoxy-3-hydroxyphenyl)acrylate hydroxyphenyl)acryloyl)oxy)-3-chloroben zyl-3-(4-acetoxy-3-hydroxyphenyl) acrylate
[0176] (E)-3-(3-hydroxy, 4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 3-Chloro-4-hydroxy benzyl alcohol (3-chloro-4-hydroxy benzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 17.
[0177] Chemical formula 17
[0178]
[0179] 1 H-NMR (400MHz, DMSO-d6) δ9.55 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H), 6.80-6.75 (m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H), 2.18 (s, 6H).
[0180] MS (ESI+): m / z 567.11 [M+H] + .
[0181] Example 15: Preparation of (E)-3-fluoro-4-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)methoxy 4-(4-hydroxy-3-methoxyphenyl)phenyl acrylate
[0182] ((E)-3-fluoro-4-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)m ethyl)phenyl-3-(4-hydroxy-3-methoxyphenyl)acrylate)
[0183] (E)-3-(3-methoxy-4-hydroxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-Fluoro 4-hydroxy benzyl alcohol (2-Fluoro 4-hydroxy benzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 18.
[0184] Chemical formula 18
[0185]
[0186] 1 H-NMR (400MHz, DMSO-d6) δ9.55 (s, 2H), 7.55-7.53 (d, 2H), 7.25-7.19 (m, 5H), 6.80-6.75 (m, 4H), 6.35-6.31 (d, 2H), 5.2 (s, 2H), 3.68 (s, 6H).
[0187] MS (ESI+): m / z 495.11 [M+H] + .
[0188] Example 16: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-fluoro Benzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate
[0189] ((E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-2-fluoroben zyl-3-(4-acetoxy-3-methoxyphenyl)acrylate)
[0190] (E)-3-(3-methoxy-4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 2-Fluoro-4-hydroxy benzyl alcohol (2-Fluoro-4-hydroxy benzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.), and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure, and column chromatography was performed using ethyl acetate / n-heptane as a developing solvent to obtain a compound according to the following chemical formula 19.
[0191] Chemical formula 19
[0192]
[0193] 1 H-NMR (400MHz, DMSO-d6) δ7.55-7.53(d, 2H), 7.35-7.19(m, 5H), 6.80-6.75(m, 4H), 6.35-6.31(d, 2H), 5.21(s, 2H), 3.68(s, 6H), 2.18(s, 6H).
[0194] MS (ESI+): m / z 579.16 [M+H] + .
[0195] Example 17: Preparation of (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-3-fluoro Benzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate
[0196] ((E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-3-fluoroben zyl-3-(4-acetoxy-3-methoxyphenyl)acrylate)
[0197] (E)-3-(3-methoxy-4-acetoxyphenyl)acrylic acid (purchased from Sigma-Aldrich) was placed in a reactor and cooled to 0°C to 5°C under a nitrogen atmosphere. After slowly adding thionyl chloride (SOCl2) (3.4 ml, exess (3 to 5 eq.)), the mixture was stirred at room temperature for more than 1 hour. After thionyl chloride was concentrated under reduced pressure, anhydrous dichloromethane (10 ml) was placed in a nitrogen atmosphere (reactor A). 3-Fluoro-4-hydroxy benzyl alcohol (3-Fluoro-4-hydroxy benzyl alcohol) was placed in reactor B. alcohol) (0.4 g, 1.0 eq.), anhydrous dichloromethane (5 ml) and triethylamine (0.7 g, 2.2 eq.) were added and stirred at room temperature for more than 30 minutes. The material in reactor A was slowly placed into reactor B at room temperature for 10 to 20 minutes, and then stirred and refluxed for more than 2 hours. After the reaction was terminated, the reaction solution was concentrated under reduced pressure and separated by column chromatography using ethyl acetate / n-heptane as a developing solvent, thereby obtaining a compound according to the following chemical formula 20.
[0198] Chemical formula 20
[0199]
[0200] 1 H-NMR (400MHz, DMSO-d6) δ7.55-7.53(d, 2H), 7.35-7.19(m, 5H), 6.94-6.73(m, 4H), 6.35-6.31(d, 2H), 5.12(s, 2H), 3.68(s, 6H), 2.18(s, 6H).
[0201] MS (ESI+): m / z 579.16 [M+H] + .
[0202] Example 18: Preparation of (E)-2-fluoro-4-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)methoxy 4-(4-hydroxy-3-methoxyphenyl)phenyl acrylate
[0203] ((E)-2-fluoro-4-((((E)-3-(4-hydroxy-3-methoxyphenyl)acryloyl)oxy)m ethyl)phenyl-3-(4-hydroxy-3-methoxyphenyl)acrylate)
[0204] The compound (E)-4-(((E)-3-(4-acetoxy-3-methoxyphenyl)acryloyl)oxy)-3-fluorobenzyl-3-(4-acetoxy-3-methoxyphenyl)acrylate (0.5 g, 1 eq.) and dioxane (5 ml) obtained by Example 17 were placed in a reactor, 2N sodium hydroxide (NaOH) (2.0 g, 5 eq.) was added, and the mixture was stirred at 50° C. for more than 3 hours. After the reaction was terminated, the mixture was cooled to room temperature, 10% hydrochloric acid (HCl) (10 ml) and ethyl acetate (15 ml) were added, and stirred for more than 30 minutes. The organic layer was extracted, dehydrated with magnesium sulfate (MgSO4), and concentrated under reduced pressure. The mixture was vacuum dried at 40° C. for more than 10 hours to obtain a compound according to Chemical Formula 21.
[0205] Chemical formula 21
[0206]
[0207] 1 H-NMR (400MHz, DMSO-d6) δ9.55 (s, 2H), 7.55-7.53 (d, 2H), 7.35-7.19 (m, 5H), 6.94-6.73 (m, 4H), 6.35-6.31 (d, 2H), 5.12 (s, 2H), 3.68 (s, 6H).
[0208] MS (ESI+): m / z 495.16 [M+H] + .
[0209] Experimental Example 1
[0210] In order to confirm whether the compound prepared in Example 1 causes skin irritation due to its toxicity to skin cells, a WST-1 assay was performed. The results are shown in Tables 1 and Figure 2 In the experiment, 1x10 4 The cells were inoculated with human keratinocytes and DMEM (Dulbecco Modified Eagle Medium) containing 10% FBS (fetal bovine serum) and 1% antibiotic-antimycotic, and cultured in an incubator at 5% CO2 and 37°C for 24 hours. Then, the cells were treated with the compound prepared in Example 1 and further cultured for 24 hours.
[0211] Table 1
[0212] distinguish Cell viability Unprocessed 100% Compound of Example 1 5uM 95.9% Compound of Example 1 10 uM 118.9%
[0213] Refer to Table 1 and Figure 2 The compound prepared in Example 1 (represented by Chemical Formula 1) showed no toxicity to keratinocytes (HaCaT) at concentrations of 5uM and 10uM, and when treated at 10uM, the cell survival rate increased instead, so it can be confirmed that it is a safe substance with low skin irritation.
[0214] Experimental Example 2
[0215] In order to confirm the antioxidant effect of the compound prepared in Example 1 on the oxidative toxicity of H2O2, the changes in cell viability caused by H2O2 were detected, and the results are shown in Tables 2 and 3. Figure 3 As shown. In the experiment, HaCaT cells were seeded in a 96-well plate and cultured under cell culture conditions for 24 hours. Then, they were treated with 1 mM H2O2, and the cells were treated with the control group and the compound prepared in Example 1 and further cultured for 12 to 16 hours. Then, in order to confirm whether the above-mentioned compounds can protect skin cells from damage induced by H2O2 oxidative toxicity, the cell viability was detected using the WST-1 assay.
[0216] Table 2
[0217]
[0218] Refer to Table 2 and Figure 3 It was confirmed that in cells treated with the compound prepared in Example 1 (represented by Chemical Formula 1) at different concentrations, the increase in reactive oxygen species caused by H2O2 treatment was significantly reduced compared with cells treated with the positive control group (treated with H2O2).
[0219] Experimental Example 3
[0220] In order to confirm the ability of the compound prepared in Example 1 to inhibit the generation of reactive oxygen species induced by H2O2, DCF-DA staining was performed. The results are shown in Table 3. Figure 4 as well as Figure 5 In the experiment, 2x10 5 After the cells were inoculated with H2O2, they were cultured for 24 hours. Then, the cells were treated with the compound prepared in Example 1 and further cultured for 24 hours. After loading with 5 mM DCF-DA for 10 minutes, they were examined by fluorescence microscopy, and the number of cells expressing DCF-DA fluorescence was counted using Image J.
[0221] Table 3
[0222]
[0223] Refer to Table 3 and Figure 4It was confirmed that in cells treated with the compound prepared in Example 1 (represented by Chemical Formula 1) at different concentrations, the increase in reactive oxygen species caused by H2O2 treatment was significantly reduced compared with cells treated with the positive control group (treated with H2O2).
[0224] As described above, the novel compound represented by Chemical Formula 1 according to the present disclosure has excellent antioxidant activity and does not show significant cytotoxicity, and thus can be used in various applications for food, medicine, and other chemical products.
[0225] The preferred embodiments of the present disclosure are described in detail above. However, the scope of rights of the present disclosure is not limited thereto. Various modifications and improvements made by technicians in the relevant field using the basic concepts of the present disclosure defined by the scope of protection claimed in the invention also fall within the scope of rights of the present disclosure.
[0226] Industrial Applicability
[0227] The present disclosure can provide a novel compound exhibiting excellent antioxidative effects, and a pharmaceutically acceptable salt or a cosmetically acceptable salt thereof, thereby being applicable to a pharmaceutical composition or a cosmetic composition.
Claims
1. A compound represented by the following chemical formula 1, an isomer or a pharmaceutically acceptable salt thereof: Chemical formula 1: In the above formula, R 1 To R 4 are independently hydrogen, C1-C 12 Alkyl, acyl or cycloalkyl, X is hydrogen, fluorine, chlorine, methyl or methoxy.
2. The compound according to claim 1, its isomer or a pharmaceutically acceptable salt thereof, wherein: The compound represented by the chemical formula 1 is selected from the group consisting of compounds having the following structures:
3. A pharmaceutical composition comprising a compound represented by the following Chemical Formula 1, an isomer thereof or a pharmaceutically acceptable salt thereof as an active ingredient: Chemical formula 1: In the above formula, R 1 To R 4 are independently hydrogen, C1-C 12 Alkyl, acyl or cycloalkyl, X is hydrogen, fluorine, chlorine, methyl or methoxy.
4. A cosmetic composition comprising a compound represented by the following Chemical Formula 1, an isomer thereof or a cosmetically acceptable salt thereof as an active ingredient: Chemical formula 1: In the above formula, R 1 To R 4 are independently hydrogen, C1-C 12 Alkyl, acyl or cycloalkyl, X is hydrogen, fluorine, chlorine, methyl or methoxy.
